Table 2

 Numbers included in Swedish Early Arthritis Register, the national ARTIS biologics cohort and its two major subsets—namely, the SSATG and the STURE regional biologics registers

Early Arthritis RegisterARTIS biologics register
Total ARTIS cohortSTURESSATG
*Patients in the Early Arthritis Register who start treatment with biological agents are automatically flagged for the ARTIS register as both registers use the same data entry and storage facility.
Data as of December 2005.
Patients entered (n) 5377*735419992210
Treatments started, No (%) 9645 (100)2745 (100)2978 (100)
Enbrel3585 (37.2)1079 (39.3)1182 (39.7)
Remicade4027 (41.8)1121 (40.8)1130 (37.9)
Humira1798 (18.6)487 (17.7)553 (18.6)
Other biological agents235 (2.4)58 (2.1)113 (3.8)
Disease activity at entry†, mean (SD)
DAS5.18 (1.29)5.30 (1.44)5.34 (1.37)5.30 (1.32)
HAQ1.10 (0.58)1.36 (0.64)1.39 (0.64)1.32 (0.66)
Disease duration at entry (years), mean (SD) 0.54 (0.25)9.7 (10)10 (10)12.7 (10.6)
Entry periods, No (%) of patients
Missing values02 (0.03)00
<199540 (0.7)000
1995–19981109 (20.6)38 (0.5)22 (1.1)2 (0.1)
1999–20011598 (29.7)2663 (36.2)657 (32.9)884 (40.0)
2002–20031328 (24.7)2155 (29.3)606 (30.3)583 (26.4)
2004–20051302 (24.2)2496 (33.9)714 (35.7)739 (33.4)
Follow up, No (%) subjects who have accrued
Missing values5 (0.1)18 (0.2)5 (0.3)2 (0.1)
<1 year818 (15.2)2369 (32.2)688 (34.4)600 (27.1)
1–3 years2252 (41.9)3472 (47.2)972 (48.6)970 (43.9)
4–5 years1061 (19.7)957 (13.0)222 (11.1)439 (19.9)
6+ years1241 (23.1)538 (7.3)112 (5.6)199 (9.0)